By Ed Susman
The cholesterol-lowering agent pitavastatin (Livalo) as primary prevention reduced the risk of major adverse cardiovascular events (MACE) among people living with HIV, the randomized REPRIEVE trial showed.
Read the full article here.
By Ed Susman
The cholesterol-lowering agent pitavastatin (Livalo) as primary prevention reduced the risk of major adverse cardiovascular events (MACE) among people living with HIV, the randomized REPRIEVE trial showed.
Read the full article here.
